TherapeuticsMD, Inc.: Form 10-K for the period ended Dec 31, 2018
Filed with the SEC on Feb 27, 2019 and accepted by EDGAR at Feb 26, 2019, 18:45 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-10-01 to 2018-12-31 | $5.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2018-01-01 to 2018-12-31 | $16.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2018-01-01 to 2018-12-31 | $2.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2018-10-01 to 2018-12-31 | $4.1m | us-gaap:GrossProfit |
| Gross profit | 12 months2018-01-01 to 2018-12-31 | $13.4m | us-gaap:GrossProfit |
| Research and development | 12 months2018-01-01 to 2018-12-31 | $27.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2018-01-01 to 2018-12-31 | $116.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2018-01-01 to 2018-12-31 | −$130.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-10-01 to 2018-12-31 | −$39.4m | us-gaap:NetIncomeLoss |
| Net income | 12 months2018-01-01 to 2018-12-31 | −$132.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-10-01 to 2018-12-31 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2018-01-01 to 2018-12-31 | −$0.59 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | −$106.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | $217.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-12-31 | $161.6m | us-gaap:Cash |
| Current assets | At period end2018-12-31 | $186.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $212.0m | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $41.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-12-31 | $114.5m | us-gaap:Liabilities |
| Long-term debt | At period end2018-12-31 | $73.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2018-12-31 | $97.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001387131-19-001471. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.